Background Several promising new diagnostic methods and algorithms for tuberculosis have been endorsed by WHO. National tuberculosis programmes now face the decision on which methods to implement and where to place them in the diagnostic algorithm.
Introduction
The past decade has seen a renewal of activity and funding dedicated to the development of improved tuberculosis diagnostics. Several promising new diag nostic methods and algorithms have been recently endorsed by WHO. [1] [2] [3] For example, Xpert MTB/RIF is a cartridge-based, automated diagnostic test that can identify Mycobacterium tuberculosis (MTB) with improved accuracy and resistance to rifampicin (RIF). However, whether these new diagnostics will replace existing methods or will be used in combination with them is not yet clear. Although new diagnostic methods and algorithms have the potential to overcome many of the weaknesses of the present diagnostic processes, they might substantially increase the demands on scarce resources and funds. 4 Before national tuberculosis pro grammes can fully scale up new tuberculosis diagnostics, policy makers need to understand the eff ects on patients, the health system, and the wider population. Failure to do so could lead to poor performance outcomes, un sustainable imple men tation, and wasted resources. 5 Trials of new tuberculosis diagnostic algorithms are essential for measuring their eff ect. [6] [7] [8] [9] However, these studies provide little quantifi cation of the eff ect that these methods will have in health systems and epidemiological contexts other than those in which the trials were done. Studies are also unable to predict longer-term eff ects of these algorithms on disease dynamics and it is usually not possible to predict how these new algorithms will aff ect the operational performance of the health system. Using an integrated modelling approach that combines detailed operational and transmission components, we assessed the eff ects and cost-eff ectiveness of several new tuberculosis diagnostic algorithms for adult pulmonary tuberculosis in Tanzania. e582 www.thelancet.com/lancetgh Vol 2 October 2014
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Study setting and diagnostic algorithms
In 2011, the incidence of tuberculosis in Tanzania was 169 per 100 000, and 38% of patients were co-infected with HIV. 10, 11 The estimated proportion of multidrug-resistant (MDR) tuberculosis was 1·1% in patients with new infection and 3·1% in those undergoing re treatment. 11, 12 We assessed the eff ects of eight WHO-endorsed diagnostic options for patients with pre sumptive tuberculosis, covering three diff erent processes and three diagnostic methods that might be diff erently targeted on the basis of HIV status (fi gure 1, table 1). The fi rst three algorithms (A) use sputum smear microscopy: A1 is the base case scenario of Ziehl-Neelsen (ZN) microscopy; A2 replaces ZN microscopy with light-emitting diode (LED) fl uorescence microscopy; and A3 uses LED fl uorescence microscopy and two sputum samples provided on the same day. 1 The algorithms in processes B and C represent the possible approaches to the use of Xpert MTB-RIF (Xpert) under present WHO recommendations.
2 B1 tests all patients with presumptive tuberculosis with Xpert; B2 and B3 target the use of Xpert to patients with presumptive tuberculosis who are HIV-positive. C1 and C2 use LED fl uorescence micro scopy as the primary method for tuberculosis diagnosis and target Xpert for smearnegative individuals with HIV infection.
The model
To assess the eff ects of diff erent diagnostic algorithms at the patient, health system, and population levels, we developed a modelling platform that integrates opera tional and transmission components. 13 The operational component used the discrete-event simu lation approach and incorporated patient and sputum sample pathways based on WHO guidelines and the present diagnostic procedure in Tanzania. [14] [15] [16] [17] We calibrated the model using data from two diagnostic centres in Tanzania (Temeke and Kibong'oto) where diff erent microscopy techniques (ZN and LED fl uorescence) were in use and where there were plans to implement Xpert. We validated the outputs from the model against the results from the 2010 National TB and Leprosy Programme (NTLP) annual reports (appendix). The transmission component followed previous epidemic modelling approaches and further incorporated the careseeking pathway of patients with tuberculosis (appendix). [18] [19] [20] The model was calibrated to the epidemiological situation of tuberculosis in Tanzania with Bayesian melding. 21 Because the operational outcomes can aff ect trans mission, and conversely transmission outcomes can aff ect operations, the two components were linked, in that output of one served as input to the other component (fi gure 2). 13 Key input variables to the operational and transmission component are shown in table 2; other variables are presented in the appendix. The frequency and accuracy of clinical diagnosis (ie, diagnosis without microbiological confi rmation) and presumptive treatment will alter the expected eff ect of new diagnostic methods and algorithms. 11 For this study, we estimated the accuracy of such diagnostic practices using the known levels of smear-positive and smear-negative tuberculosis in Tanzania in conjunction with estimates of the sensitivity and specifi city of microscopy and the sensitivity of clinical judgment in smear-negative cases from published work 7, 37 (details of these calculations are shown in the appendix). Operational and transmission components of the model have been previously published and can be found in the appendix. 13, 20, 37 
Cost-eff ectiveness analysis
We did cost-eff ectiveness analyses to compare diff erent diagnostic options. The incremental cost of implementing each alternative diagnostic option was derived from the Tanzanian health system perspective, and included the additional annual running costs (eg, consumables, tuberculosis and MDR-tuberculosis drugs, radiographs, equipment maintenance, and laboratory personnel) and the investment costs (eg, microscopes and the equipment related to Xpert implementation) (table 2, appendix). Following advice from the NTLP, other overhead costs were assumed to be unaff ected by a change in the diagnostic algorithm. Patients' costs were not collected or included in this study, but an indication of how they could be used in the model is given in the appendix. Because the introduction of new tuberculosis diagnostics is expected to improve the survival of patients co-infected with tuberculosis and HIV, we estimated the incremental costs from additional antiretroviral therapy (ART) on the basis of the projected number of deaths from tuberculosis and HIV co-infection. The population eff ect on tuberculosis epidemiology was summarised using dis abilityadjusted life-years (DALYs) without age weigh ting. 36, 38 Costs and DALYs were calculated over 10 years with an annual discount rate of 3%. 39 We calculated the average cost-eff ectiveness ratio (ACER) by comparing each alternative diagnostic option to the base case scenario (A1, table 1). Because the alternative diagnostic options are mutually exclusive interventions that compete for the same resources, we also calculated the incremental costeff ectiveness ratios (ICER) to compare one option with the next less-eff ective option. 40 The estimated ICER was compared with the willingness-to-pay threshold for Tanzania (US$599 based on gross domestic product [GDP] per capita in 2012). 41, 42 
Uncertainty and sensitivity analysis
We did an uncertainty analysis using 1000 posterior simulations to estimate the 95% credible intervals (95% CrI) of the population-level eff ect on incidence, prevalence, mortality, and DALYs. The 95% CrIs are the Bayesian framework equivalent of confi dence intervals in the frequentist framework. 43 We did one-way sensitivity analyses to explore the eff ect of input variables on ACER and ranking of diagnostic options using 1000 posterior simulations (appendix).
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. IL and H-HL had full access to all data in the study. Together with SBS they had fi nal responsibility for the decision to submit for publication.
Results
Full rollout of Xpert (B1) would have the greatest patient-level benefi ts among the alternative diagnostic options (table 3). The improved diagnostic sensitivity and the need for only one sputum sample for Xpert reduces mean patient visits for diagnosis by 1·2 (95% CrI 1·1-1·3) visits, time to start treatment by Sensitivity of ZN microscopy for HIV-negative cases 72·3% As above
Specifi city of ZN microscopy for HIV-positive cases 100·0% As above
Specifi city of ZN microscopy for HIV-negative cases 99·4% As above
Sensitivity of clinical diagnosis 51·9% Swai and colleagues, 2011 24 Sensitivity improvement of LED fl uorescence microscopy over ZN microscopy +6·0% WHO, 2011 25 Specifi city improvement of LED fl uorescence microscopy over ZN microscopy 0·0% As above Sensitivity improvement of same-day LED fl uorescence microscopy over ZN microscopy -2·8% WHO, 2011 1 Specifi city improvement of same-day LED fl uorescence microscopy over ZN microscopy 0·0% As above Similarly, full rollout of Xpert (B1) would have the greatest eff ect at the population level. The epidemiological eff ect is projected to be the greatest on tuberculosis prevalence, followed by tuberculosis mortality, and tuberculosis incidence (fi gure 3). Com pared with the baseline algorithm (A1), full imple mentation of Xpert (B1) would prevent 17 000 (95% CrI 8800-26 600) cases of incident tuberculosis and 39 700 (95% CrI 27 600-53 000) tuberculosis deaths over 10 years (table 5) . In addition to the eff ect on tuberculosis epidemiology, new diagnostics would increase the number of people on ART because of improved survival of patients co-infected with tuber culosis and HIV. Assuming that the coverage of ART would gradually reach 80% in 10 years, 10 diff erent diagnostic options would result in 3900 (95% CrI 600-8900) (A2) to 19 600 (95% CrI 3300-34 600) (B1) additional person-years on ART. Compared with the baseline algorithm, full imple mentation of Xpert (B1) would prevent the largest number of DALYs (346 000, 95% CrI 247 000-475 000) over 10 years (table 5) . Other diagnostic algorithms would have less eff ect on DALYs, with the benefi ts ranging from 57 900 (A2) to 162 800 (B3) DALYs averted.
In the cost-eff ectiveness analysis, the ACER of alternative diagnostic options ranged from $29 to $240 per disability-adjusted life-year (DALY) averted compared with ZN microscopy (A1), with the incremental cost varying between $1·7 million and $36·9 million ( 
Figure 4: Sustainability versus cost-eff ectiveness (average cost-eff ectiveness ratio, ACER) versus disability-adjusted life-years (DALYs) averted
The size of the circles shows the scale of benefi ts from each intervention measured in DALYs averted over 10 years relative to the base case of Ziehl-Neelsen microscopy. LED=light-emitting diode.
same-day LED fl uorescence microscopy (A3) and Xpert full rollout (B1) because they produce DALY gains at a higher incremental cost (appendix). The ICER of Xpert full rollout is $169 per DALY averted (95% CrI 104-265), followed by same-day LED fl uorescence microscopy ($45, 95% CrI 25-74) and LED fl uorescence micro scopy ($29, 95% CrI 6-59) (table 5) . The ICERs for all three alternative algorithms are below the willingness-to-pay threshold for Tanzania ($599).
In one-way sensitivity analyses, the variables having most eff ect on ICER were the natural history variables of tuberculosis and HIV (eg, reactivation rate, natural cure rate, duration of infectiousness, and the transmission variable) whose prior and posterior ranges of uncertainty were wide, showing insuffi cient understanding of these variables (appendix). Overall, the estimated ICERs were robust to uncertainty of most input variables. We also changed the assumption on ART so that the coverage increased to 80% in 5 years, and the results were similar (appendix). We further set the variables with greatest eff ect in the sensitivity analysis to the extreme values (2·5 and 97·5 percentile of the posterior distribution), and found that the ranking of diagnostic options remained unchanged (appendix).
Discussion
We have assessed the eff ect of several promising tuberculosis diagnostic options that are being considered by many national tuberculosis programmes, and have identifi ed three cost-eff ective strategies in the context of Tanzania: full rollout of Xpert MTB/RIF (B1) at $169 per DALY averted, followed by same-day LED fl uorescence microscopy (A3) at $45, and LED fl uorescence microscopy (A2) at $29 per DALY averted.
According to the updated recommendations from WHO, Xpert should be used as the initial diagnostic test in individuals suspected of having HIV-associated tuberculosis (strong recommendation). 2 In settings such as Tanzania where the prevalence of HIV infection is high, all presumptive tuberculosis cases can be considered as presumptive cases of HIV-associated tuberculosis, justifying the full rollout of Xpert as the initial diagnostic test. However, many HIV-endemic countries (eg, Tanzania) might see the previous recommendation as suggesting Xpert should be used only on presumptive tuberculosis cases with known HIV infection. In Tanzania, because of the high cost of the test, Xpert was seen as a follow-on test to microscopy rather than a replacement test. Our analysis showed that, in settings similar to that in Tanzania, targeted use of Xpert in HIVpositive presumptive tuberculosis cases (B2 and B3) and in HIV-positive and smear-negative cases (C1 and C2) is not cost-eff ective compared with full rollout of Xpert or same-day LED fl uorescence microscopy.
The reason for the inferior cost-eff ectiveness performance of targeted implementation is that the projected gains in DALYs in most cases are lower than those projected from implementing same-day LED fl uorescence microscopy, and the projected cost is substantially higher. The targeted approaches considered in our analysis focused on HIV-positive presumptive tuberculosis cases. Because the life expectancy of HIVpositive individuals is shorter than that of HIV-negative individuals, the potential gain in life-years (and DALYs) of preventing a death from tuberculosis in a HIV-positive patient would be smaller than that of preventing a death from tuberculosis in a HIV-negative patient. Much of the ART cost would be preserved in the targeted approach, resulting in inferior cost-eff ectiveness of the targeted approach, showing that if the benefi t of new diagnostic algorithms is measured by the overall improved years of healthy life (ie, DALYs averted), the eff ect (or lack of eff ect) on the HIV-negative population is an essential element of any assessment. Nonetheless, our results did not suggest that access to improved diagnosis (Xpert) should be denied to the HIV-infected population. In fact, full rollout of Xpert is the only way to ensure all HIVpositive patients receive Xpert diagnosis in the context of Tanzania, because most HIV-positive individuals do not know their HIV status at the point of tuberculosis diagnostic testing.
Among the cost-eff ective diagnostic options, the decision on which one to use will depend on the costeff ectiveness ratio of other health interventions being considered in Tanzania. If the health-related budget in Tanzania can aff ord a health intervention with a costeff ectiveness ratio of $599 (GDP per head in Tanzania, 2012) per DALY, the government should consider full scale-up of Xpert (B1), which has an average ICER of $169 (95% CrI 104-265) per DALY. We note that costeff ectiveness does not necessarily imply that the interventions are aff ordable or sustainable. The ICER of each intervention needs to be weighed against the associated incremental costs. The projected 10-year incremental cost to the tuberculosis programme of Xpert scale-up ($28·3 million) represents an increase of about 25% in funds to the present tuberculosis programme. Additionally, an incremental cost of $8·6 million to the HIV programme will be needed as a result of the additional cost of ART (see appendix for a breakdown). Without a major ongoing injection of funds into the Tanzanian NTLP, the full scale-up of Xpert appears to be unsustainable at present. Appropriate funding will need to be mobilised to translate this into clinical practice.
By contrast with the fi ndings from the present study, Theron and colleagues 44 reported that the use of Xpert was not associated with lower tuberculosis-related morbidity in a multicentre randomised trial from four African countries. A substantial percentage of treatment episodes in this fi eld trial were based on clinical diagnosis in the absence of microbiological identifi cation of Mycobacterium tuberculosis (66% of those treated for tuberculosis in the smear microscopy group and 43% of those treated in the Xpert group). In settings where the rate of empirical treatment is high, most individuals with tuberculosis coming for diagnosis will receive treatment, whichever diagnostic method is used. Therefore, the ability of any new diagnostic methods and algorithms to identify additional tuberculosis cases will be limited. 20, 45 Because empirical treatment decisions are not routinely taken in Tanzania, the diff erence in eff ect of Xpert between our study and the Theron study might be explained by diff erent rates of empirical treatment. Additionally, the cost-eff ectiveness of an intervention will depend on the accuracy (sensitivity and specifi city) of empirical diagnosis in smear-negative cases. If the specifi city were lower than assumed in our study (<95%), the benefi ts of Xpert (B1) would be increased and the ICER reduced because of a larger reduction in falsepositive diagnosis of tuberculosis.
Compared with ZN microscopy, we estimated that the ACER for full rollout of Xpert (B1) would be $109 (95% CrI 72-144) per DALY averted. Vassall and colleagues 46 estimated the ACER of Xpert to be $52-138 per DALY in 1 year using decision analytical models of tuberculosis in India, South Africa, and Uganda. 46 In another calibrated, dynamic mathematical model of fi ve southern African countries (Botswana, Lesotho, Namibia, South Africa, and Swaziland), Menzies and colleagues 47 reported the ACER of Xpert to be $959 (95% CrI 633-1485) per DALY over a 10-year period (panel). In addition to the expected diff erence in ACER due to diff erent epidemiology of tuberculosis and HIV, we note that these ACER estimates cannot be directly compared for a number of reasons. First, our study and the Menzies study applied epidemic models that incorporated the eff ect on tuberculosis transmission, whereas the Vassall study used static models that did not account for transmission eff ects (and therefore might underestimate the overall eff ect). Second, when measuring DALYs averted by new diagnostics, our study and the Vassall study included the eff ect on future disease burden (eg, a tuberculosis death averted in a patient with a life expectancy of 20 years would contribute 20 years of DALY), whereas the Menzies study accounted for the eff ect on prevalent disease burden over the study period (in the previous example, the DALY contribution would be 10 years if the study period is 10 years). We repeated our ICER analysis using a similar prevalence approach as Menzies and colleagues 47 and found that the estimated ICER increased from $169 (95% CrI 104-265) to $1491 (95% CrI 973-2523) (table 5) . Third, our study and the Menzies study included the cost of ART in the analysis, whereas the Vassall study did not.
Although we focused only on Tanzania in the present analysis, our key fi ndings on the rank of alternative diagnostic options should be generalisable to countries of similar operational and epidemiological situations (eg, countries with high HIV and low MDR tuberculosis, and similar health system infrastructures). In other settings, the approach in our study, which includes important details related to both infrastructure and epidemiology, allows countries to make the best use of modelling to inform local decision making. As this type of approach is applied in additional settings we might learn more generalisable lessons about which alternatives do best in diff erent settings.
The operational component of this study has enabled the detailed interactions and bottlenecks of the health system to be modelled, which helps to understand the eff ect of each option on staff use, the number of Xpert machines and microscopes, the level of diagnostic lost to follow-up, and the time to start treatment. This detailed approach will be of particular value for the prioritisation and rollout of new diagnostics to individual districts in Tanzania. Additionally, when combined with data collection from patients, the operational component would help to assess how the observed reductions in patient visits aff ect patient costs (how this analysis could be done is shown in the appendix).
The robustness of conclusions from this study is aff ected by the uncertainty of variables and assumptions on model structure. Data availability and accuracy can be a constraint with modelling. In this study some countrylevel input data and natural history variables had a high degree of uncertainty. We did a sensitivity analysis to explore the eff ect of this uncertainty on the estimated ICERs. Results of the sensitivity analysis suggest that the ranking of diagnostic options is robust to uncertainty in the input variables. We also note that a full health system
Panel: Research in context
Systematic review A systematic review of tuberculosis diagnostic modelling was done in April, 2013, by the TB Modelling and Analysis Consortium (TB MAC). 48 The review focused on modelling studies of new diagnostics for active tuberculosis disease. 31 studies were identifi ed, including 16 cost-eff ectiveness analyses using decision analytical modelling or epidemic modelling methods. Seven studies assessed the eff ect of Xpert MTB/RIF when it is used in people with HIV initiating antiretroviral therapy or people with presumptive tuberculosis. Most of these modelling studies focused on the population-level eff ect of new diagnostics, and none examined the eff ect at the patient level or the health system level. No modelling studies compared alternative algorithms of Xpert use suggested by WHO.
Interpretation
Our study is the fi rst modelling study to investigate the potential eff ects on the patient, the health system, and the population for a range of tuberculosis diagnostic methods and algorithms. Our results provide a wish list for policy makers when deciding to deploy new diagnostics in a country. The engagement with partners from the Tanzania National TB and Leprosy Programme throughout the modelling study enabled the results to be communicated to and considered by the policy makers.
costing model was not constructed in this study; instead unit cost estimates were largely provided by experts from the national tuberculosis programme. A more detailed health system costing model could provide better information to estimate the ICERs and sustainability of diff erent diagnostic options. One limitation of the study is that MDR tuberculosis was not explicitly considered in the transmission component in view of the low prevalence of MDR tuberculosis in patients with tuberculosis. Therefore, we assumed that the proportion of MDR tuberculosis in incident tuberculosis cases remained unchanged over the projection period. Our analysis might have underestimated the cost-eff ectiveness of Xpert because the use of Xpert could reduce the transmission of MDR tuberculosis. National policy makers should take account of other local infrastructural factors, such as availability of robust power supplies, when considering alternative diagnostic algorithms, because a modelling analysis cannot account for all the practical challenges that might arise from implementation of a new method such as Xpert. Additionally, to gain the benefi ts outlined in this study, strong project management, good supply chains, commitment from all staff , and adherence to revised diagnostic processes are all necessary. Lastly, there are technical limitations in doing real-time linkage of two models. In particular, linkage across both components has not been possible in the uncertainty analysis. Further research is necessary to fully integrate the two components on one single modelling platform.
We have investigated the eff ects of alternative diagnostic approaches on the patient, the health system, and the wider community. This study is the fi rst of its kind to bring such comprehensive information to national policy makers and other interested stakeholders. An important next step is to undertake a policy transfer analysis to prospectively understand whether and how this new knowledge will be used to inform the actual decisionmaking process at the programme level. Meanwhile, as a way of validating the approach, the programme must monitor the key operational (level of empirical treatment, diagnostic lost to follow-up rate, and time from diagnosis to treatment) and epi demiological (incidence, prevalence, and mortality) indicators after the implementation of the selected diagnostic option.
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